Dr Talia Golan (Chaim Sheba Medical Center, Tel-Hashomer, Israel) and Prof Eric Van Cutsem (University of Leuven, Leuven, Belgium) speak at the ESMO GI 2019 meeting in Barcelona about the latest advances in pancreatic cancer.
Prof Van Cutsem opens with some important background on the current status and difficulty of pancreatic cancer treatment to date.
Dr Golan builds on this by reflecting on some eye-opening geographic diagnostic data from early on in the POLO trial.
Following this she expands on other important developments, particularly the response of BRCA patients, and how the design of a PARP inhibitor based treatment was outlined.
The experts then discuss the process of maintenance therapies, and how this varies across various areas in Europe.
They further discuss the feasibility of germline testing, and how to address the various genetic alterations that are being presented.
|Current landscape of germline BRCA mutated pancreatic cancer|
|Maintenance therapy and PARP inhibition in pancreatic cancer|
|Global management strategies for germline BRCA mutated pancreatic cancer|
|Implementation of germline testing to identify genetic mutations in the clinic|
This programme has been supported by an unrestricted educational grant from AstraZeneca.